We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Read MoreHide Full Article
Intellia Therapeutics, Inc. (NTLA - Free Report) is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron Pharmaceuticals (REGN - Free Report) for the development of NTLA-2001.
NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients and ATTR amyloidosis with cardiomyopathy (ATTR-CM) patients. The phase III MAGNITUDE study evaluating NTLA-2001 to treat ATTR amyloidosis with cardiomyopathy is currently ongoing.
If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001.
Intellia has received the FDA alignment for a pivotal phase III study design, which will support a biologics license application (BLA) filing for NTLA-2001 as a single-dose treatment in ATTRv-PN pending review of its investigational new drug application. The phase III study is likely to begin by 2024-end.
NTLA-2001 is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for NTLA-2001, REGN shares 25% of the development costs and commercial profits.
The collaboration with Regeneron has given a boost to the company to develop its pipeline.
Shares of Intellia have declined 14.8% so far this year compared with the industry’s decrease of 5.1%.
Image Source: Zacks Investment Research
Intellia’s clinical-stage pipeline comprises another gene-editing candidate, NTLA-2002, which is currently being developed for treating hereditary angioedema (HAE). Earlier this month, the company reported encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for the given indication.
Per management, the long-term data has bolstered the candidate's potential as a groundbreaking treatment for HAE as patients experienced durable elimination of their HAE attacks in the ongoing phase I/II study.
The company has completed enrollment in the phase II portion of its study. The company plans to begin a pivotal phase III study on NTLA-2002 in the HAE indication in the second half of 2024.
This apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024.
Though Intellia is making good progress with its encouraging pipeline development, failure in ongoing studies will be a huge setback for the company.
Meanwhile, several companies are also using the CRISPR/Cas9 gene editing technology to address various diseases in specific areas. Companies like Editas Medicine, CRISPR Therapeutics and Precision BioSciences are developing their respective in-vivo and ex-vivo therapies. As a result, competition in the targeted space remains an overhang for Intellia.
In the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed from $3.42 to $2.47. Loss per share estimates for 2025 have narrowed from $3.36 to $2.55. Year to date, shares of ACRV have surged 56.9%.
ACRV’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining one occasion, the average surprise being 3.56%.
In the past 60 days, estimates for Aligos Therapeutics’ 2024 loss per share have narrowed from 84 cents to 73 cents, while loss per share estimates for 2025 have narrowed from 82 cents to 71 cents. Year to date, shares of ALGS have declined 23.5%.
ALGS’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, the average surprise being 7.83%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia Therapeutics, Inc. (NTLA - Free Report) is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron Pharmaceuticals (REGN - Free Report) for the development of NTLA-2001.
NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients and ATTR amyloidosis with cardiomyopathy (ATTR-CM) patients. The phase III MAGNITUDE study evaluating NTLA-2001 to treat ATTR amyloidosis with cardiomyopathy is currently ongoing.
If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001.
Intellia has received the FDA alignment for a pivotal phase III study design, which will support a biologics license application (BLA) filing for NTLA-2001 as a single-dose treatment in ATTRv-PN pending review of its investigational new drug application. The phase III study is likely to begin by 2024-end.
NTLA-2001 is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for NTLA-2001, REGN shares 25% of the development costs and commercial profits.
The collaboration with Regeneron has given a boost to the company to develop its pipeline.
Shares of Intellia have declined 14.8% so far this year compared with the industry’s decrease of 5.1%.
Image Source: Zacks Investment Research
Intellia’s clinical-stage pipeline comprises another gene-editing candidate, NTLA-2002, which is currently being developed for treating hereditary angioedema (HAE). Earlier this month, the company reported encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for the given indication.
Per management, the long-term data has bolstered the candidate's potential as a groundbreaking treatment for HAE as patients experienced durable elimination of their HAE attacks in the ongoing phase I/II study.
The company has completed enrollment in the phase II portion of its study. The company plans to begin a pivotal phase III study on NTLA-2002 in the HAE indication in the second half of 2024.
This apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024.
Though Intellia is making good progress with its encouraging pipeline development, failure in ongoing studies will be a huge setback for the company.
Meanwhile, several companies are also using the CRISPR/Cas9 gene editing technology to address various diseases in specific areas. Companies like Editas Medicine, CRISPR Therapeutics and Precision BioSciences are developing their respective in-vivo and ex-vivo therapies. As a result, competition in the targeted space remains an overhang for Intellia.
Intellia Therapeutics, Inc. Price and Consensus
Intellia Therapeutics, Inc. price-consensus-chart | Intellia Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. (ACRV - Free Report) and Aligos Therapeutics, Inc. (ALGS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed from $3.42 to $2.47. Loss per share estimates for 2025 have narrowed from $3.36 to $2.55. Year to date, shares of ACRV have surged 56.9%.
ACRV’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining one occasion, the average surprise being 3.56%.
In the past 60 days, estimates for Aligos Therapeutics’ 2024 loss per share have narrowed from 84 cents to 73 cents, while loss per share estimates for 2025 have narrowed from 82 cents to 71 cents. Year to date, shares of ALGS have declined 23.5%.
ALGS’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, the average surprise being 7.83%.